Therapeutic Asset Ratings
160 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer
renal cell carcinoma
Bristol-Myers Squibb
P1/2
CC
(47)
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer
non-small cell lung carcinoma
Bristol-Myers Squibb
P1/2
CC
(47)
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer
triple-negative breast carcinoma
Bristol-Myers Squibb
P1/2
CC
(47)
Pumitamig
triple-negative breast carcinoma
Bristol-Myers Squibb
P1/2
CC
(47)
Relatlimab
Hodgkins lymphoma
Bristol-Myers Squibb
P1/2
CC
(47)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
lung cancer
Bristol-Myers Squibb
P1/2
CC
(46)
Relatlimab
non-Hodgkin lymphoma
Bristol-Myers Squibb
P1/2
CC
(46)
Bms-936558-01
head and neck squamous cell carcinoma
Bristol-Myers Squibb
P1/2
CC
(45)
BMS-986470
Healthy Volunteers
Bristol-Myers Squibb
P1/2
CC
(45)
BMS-986523
Advanced Solid Malignancies
Bristol-Myers Squibb
P1/2
CC
(45)
Cetuximab
Advanced Solid Malignancies
Bristol-Myers Squibb
P1/2
CC
(45)
Cyclophosphamide
Advanced Solid Malignancies
Bristol-Myers Squibb
P1/2
CC
(45)
Epirubicin
Advanced Solid Malignancies
Bristol-Myers Squibb
P1/2
CC
(45)
Famotidine
Healthy Volunteers
Bristol-Myers Squibb
P1/2
CC
(45)
Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer
head and neck squamous cell carcinoma
Bristol-Myers Squibb
P1/2
CC
(45)
Orm-6151
Solid Tumours
Bristol-Myers Squibb
P1/2
CC
(45)
Pembrolizumab
Advanced Solid Malignancies
Bristol-Myers Squibb
P1/2
CC
(45)
Pumitamig
head and neck squamous cell carcinoma
Bristol-Myers Squibb
P1/2
CC
(45)
Repotrectinib
Healthy Volunteers
Bristol-Myers Squibb
P1
CC
(44)
11c-bms-986196
multiple sclerosis
Bristol-Myers Squibb
P1
CC
(43)
BMS-986463
ovarian serous adenocarcinoma
Bristol-Myers Squibb
P1
CC
(43)
BMS-986500
ovarian cancer
Bristol-Myers Squibb
P1
CC
(43)
Mrtx1719
malignant peripheral nerve sheath tumor
Bristol-Myers Squibb
P1
CC
(43)
Orm-6151
cancer
Bristol-Myers Squibb
P1
CC
(43)
Bms-936558-01
ovarian neoplasm
Bristol-Myers Squibb
P1/2
CC
(43)
Showing 76 to 100 of 160 assets
Previous
Page 4 of 7
Next
